Open-Label Comparative Clinical Study of Chlorproguanil−Dapsone Fixed Dose Combination (Lapdap™) Alone or with Three Different Doses of Artesunate for Uncomplicated Plasmodium falciparum Malaria
Table 5
Treatment emergent investigational drug-related adverse events reported during the study and the most common adverse events reported in ≥10% of patients in any treatment group for the intent to treat (safety) population.